Safety of Repeated Administration of Parenteral Ketamine for Depression
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
The objective of this study was to investigate the safety of repeated parenteral ketamine for depression. An electronic survey inquiring about the frequency of adverse events was distributed to providers of parenteral ketamine for depression. In addition, the investigators conducted a search of published studies describing six or more repeated parenteral ketamine treatments administered to individuals for depression, and extracted reported adverse events. The survey was sent to 69 providers, of which 36 responded (52% response rate); after eliminating those that were incomplete, 27 were included in the analysis. The providers in the analysis collectively reported treating 6630 patients with parenteral ketamine for depression, one-third of whom received more than 10 treatments. Only 0.7% of patients experienced an adverse effect that required discontinuation of ketamine. Psychological distress during the treatment was the most frequent cause. Other adverse events were extremely rare (such as bladder dysfunction (0.1%), cognitive decline (0.03%) and psychotic symptoms (0.03%)). Among the 20 published reports of repeated parenteral ketamine treatments, rates of significant adverse events resulting in discontinuation were low (1.2%). The rate of adverse effects reported in the survey and the published literature is low, and suggests that long-term treatment of depression with ketamine is reasonably safe.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Minimal clinical research supports these findings, suggesting that risks of dependency are extremely low when ketamine is administered in a medical setting [158-160]”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [159]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643 · cited 2×
“The mainstay of treatment at present is antidepressant medications; however, it is estimated that at least half the patients treated with conventional antidepressants do not experience remission despite multiple trials of different agents [3].”
BackgroundDepression Is the Leading Cause of Disability Around the World
Friedrich, M. J. (2017) · JAMA · doi:10.1001/jama.2017.3826 · Cited by 1,459 · cited 1×
“Depression is one of the leading causes of disability worldwide, with an estimated 322 million people living with depression [1,2].”
BackgroundMurrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.022 · Cited by 786 · cited 1×
“[20] reported administering six ketamine infusions (0.”
Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression
aan het Rot, M., Collins, K. A., Murrough, J. W., Perez, A. M., Reich, D. L., Charney, D. S., & Mathew, S. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.08.038 · Cited by 690 · cited 1×
“[19] administered six ketamine infusions (0.”
Effects of Ketamine in Normal and Schizophrenic Volunteers
Lahti, A. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00243-3 · Cited by 674 · cited 1×
“The most cited concerns are addiction [9], damage to the urinary tract [10], psychosis [11] and cognitive decline [12].”
BackgroundMorgan, C. J. A., Curran, H. V., & the Independent Scientific Committee on Drugs (ISCD) (2012) · Addiction · doi:10.1111/j.1360-0443.2011.03576.x · Cited by 667
Side-effects associated with ketamine use in depression: a systematic review
Short, B., Fong, J., Galvez, V., Shelker, W., & Loo, C. K. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30272-9 · Cited by 558 · cited 1×
“However, the authors also noted that most studies published to date involve single or small number infusions in subjects, and there is thus a dearth of data regarding long-term outcomes [14].”
BackgroundSingh, J. B., Fedgchin, M., Daly, E. J., De Boer, P., Cooper, K., Lim, P., Pinter, C., Murrough, J. W., Sanacora, G., Shelton, R. C., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16010037 · Cited by 525 · cited 1×
“[28] conducted a study in which adults with TRD received IV ketamine infusions (0.”
BackgroundAttenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism
Williams, N. R., Heifets, B. D., Blasey, C., Sudheimer, K., Pannu, J., Pankow, H., Hawkins, J., Birnbaum, J., Lyons, D. M., Rodriguez, C. I., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18020138 · Cited by 519 · cited 1×
“It is notable that we did not identify a single case of reported addiction attributable to parenteral ketamine administration for treating depression, in either our survey or the literature review, given that this one of the most commonly expressed concerns regarding repeated ketamine injections for treating TRD [8,9,…”
BackgroundPhillips, J. L., Norris, S., Talbot, J., Birmingham, M., Hatchard, T., Ortiz, A., Owoeye, O., Batten, L. A., & Blier, P. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18070834 · Cited by 418 · cited 1×
“[24] conducted a study of 41 subjects with treatment-resistant depression, who received single blinded infusions of ketamine and midazolam, followed by six open-label ketamine infusions administered thrice weekly for two weeks, followed by another four weekly infusions.”
Background
Cited by
Smith-Apeldoorn, S. Y., Veraart, J. K., Spijker, J., Kamphuis, J., & Schoevers, R. A. (2022) · The Lancet Psychiatry · doi:10.1016/s2215-0366(22)00317-0 · Cited by 169
Martinotti, G., Chiappini, S., Pettorruso, M., Mosca, A., Miuli, A., Di Carlo, F., D’Andrea, G., Collevecchio, R., Di Muzio, I., Sensi, S. L., et al. (2021) · Brain Sciences · doi:10.3390/brainsci11070856 · Cited by 111
Ketamine in neuropsychiatric disorders: an update
Johnston, J. N., Kadriu, B., Kraus, C., Henter, I. D., & Zarate, C. A. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01632-1 · Cited by 108
Ceban, F., Rosenblat, J. D., Kratiuk, K., Lee, Y. L., Rodrigues, N. B., Gill, H., Subramaniapillai, M., Nasri, F., Lui, L. M. W., Lipsitz, O., et al. (2021) · CNS Drugs · doi:10.1007/s40263-021-00846-5 · Cited by 102
“A survey of 6630 patients treated with ketamine for depression ascertained that hypertension did not lead to any instances of treatment discontinuation [14].”
BackgroundThe abuse liability of ketamine: A scoping review of preclinical and clinical studies
Le, T. T., Cordero, I. P., Jawad, M. Y., Swainson, J., Di Vincenzo, J. D., Jaberi, S., Phan, L., Lui, L. M. W., Ho, R., Rosenblat, J. D., et al. (2022) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2022.04.035 · Cited by 82
Van Amsterdam, J., & Van Den Brink, W. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1949454 · Cited by 44
“ment of depression with ketamine is relatively safe [84].”
BackgroundGarel, N., Drury, J., Lévesque, J. T., Goyette, N., Lehmann, A., Looper, K. J., Erritzøe, D., Dames, S., Turecki, G., Rej, S., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1268832 · Cited by 40
“As a consequence, the most common strategy for prolonging ketamine’s benefits is simply to readminister ketamine (27, 28), despite a relative dearth of evidence for this practice’s long-term safety, efficacy, and feasibility (29).”
BackgroundNg, J., Lui, L. M. W., Rosenblat, J. D., Teopiz, K. M., Lipsitz, O., Cha, D. S., Xiong, J., Nasri, F., Lee, Y. L., Kratiuk, K., et al. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05767-1 · Cited by 41
“Currently, there are limited studies that investigate the long-term safety (≥ 6 months) of IV ketamine and IN esketamine treatments (Feifel et al. 2020; Findeis et al. 2020; Short et al. 2018).”
BackgroundChrenek, C., Duong, B., Khullar, A., McRee, C., Thomas, R. K., & Swainson, J. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1283733 · Cited by 29
Ingrosso, G., Cleare, A. J., & Juruena, M. F. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241303597 · Cited by 28
Craving and addictive potential of esketamine as side effects?
Orsolini, L., Salvi, V., & Volpe, U. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2071422 · Cited by 18
Ketamine for Bipolar Depression: Biochemical, Psychotherapeutic, and Psychedelic Approaches
Bennett, R., Yavorsky, C., & BRAVO, G. L. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.867484 · Cited by 16
“Serious adverse events associated with ketamine treatment in a legal setting include respiratory distress and seizure (64).”
BackgroundHovda, N., Gerrish, W. G., Frizzell, W., & Shackelford, R. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.10.120 · Cited by 15
Elwyn, R., Mitchell, J., Kohn, M. R., Driver, C., Hay, P., Lagopoulos, J., & Hermens, D. F. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105122 · Cited by 11
Efficacy of ketamine versus esketamine in the treatment of perioperative depression: A review
Wen, W., Zhao, W., Xia, X., Duan, X., Zhang, L., Lin, D., Qi, Z., Wang, S., Gao, M., Liu, C., et al. (2024) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2024.173773 · Cited by 9
Gałecki, P., Bliźniewska-Kowalska, K. M., Cubała, W. J., Depukat, A., Mosiołek, A., RYBAKOWSKI, J. K., Samochowiec, J., Sobolewski, B., Szulc, A., & Dudek, D. (2024) · Psychiatria Polska · doi:10.12740/pp/189494 · Cited by 12
“Feifel and colleagues [61], in their study of a sample of 6630 patients receiving repeated (but not necessarily maintenance) parenteral administration of ketamine for the treatment of depression, indicated that only 0.7% of patients experienced adverse effects that required discontinuation of…”
InfluentialSajid, S., Mann, J. J., & Grunebaum, M. F. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03255-0 · Cited by 10
“Consistent with previous studies, this review found that repeated and single administrations of ketamine and S-ketamine have common, short-lived side effects, but generally are well tolerated [8, 68, 69].”
Gutiérrez, G., Vázquez, G. H., Ravindran, N., Lam, R. W. M., Giacobbe, P., Ganapathy, K., Kowara, A., Do, A., Baskaran, A., Nestor, S. M., et al. (2025) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986251347360 · Cited by 8
“20 For instance, a survey conducted by Feifel et al., 21 reported that adult patients receiving ketamine treatment for MDD-TRD did not report the development of addiction symptoms associated with this treatment, but this relied on a survey of ketamine providers.”
Mathai, D. S., Cluck, M., Aslam, A. M., Amato, E., Azam, A., Banov, M., Barrett, K. A., Bonnett, C. J., Feifel, D., Grundmann, N., et al. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.121970 · Cited by 7
Self-citationTamman, A. J. F., Anand, A., & Mathew, S. J. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2049754 · Cited by 6
“5% of patients [48], with tolerance increasing as treatment”
BackgroundJennings, S. D., Hagarty, D. P., Logue, J. B., Crawford, M., Saland, S. K., & Kabbaj, M. (2025) · eNeuro · doi:10.1523/eneuro.0452-24.2025 · Cited by 4
“Ketamine-seeking behaviors are enhanced in some individuals with MDD and comorbid SUD following treatment (Feifel et al., 2020; Chubbs et al., 2022), which may suggest that ketamine-seeking behaviors following treatment are increased in males with a history of alcohol drinking and MDD.”
Gałuszko‐Węgielnik, M., Włodarczyk, A., Cubała, W. J., Wilkowska, A., Górska, N., & Słupski, J. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.705190 · Cited by 7
“The antidepressant effect of ketamine persists days or weeks beyond treatment, and the assumption may be that the rapid effect will appear, nevertheless, in subsequent ketamine treatment (1).”
BackgroundSevelius, J. M., Golden, R. L., Stott, B. L., Kozicz, N. O., Mukerjee, R., Cluesman, S. R., Jones, T., & Cornelius, T. M. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1727487 · Cited by 5
Cohen, R., Bastos, J., Cunha, C., Marguilho, M., Sancho, A. V., Silva, M. J. M., King, F., & Castro-Rodrigues, P. (2026) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2026.02.001 · Cited by 3
Ketamine for depressive symptoms: A retrospective chart review of a private ketamine clinic
Juby, V. M., Paruk, S., Tomita, M., & Chiliza, B. (2024) · South African Journal of Psychiatry · doi:10.4102/sajpsychiatry.v30i0.2176 · Cited by 4
“22,23 While the number of randomised control trials showing that the efficacy and safety of ketamine has increased dramatically since 2000, there is limited evidence demonstrating its real-world effectiveness and safety.”
BackgroundMorphological correlates of anxiety-related experiences during a ketamine infusion
Graf, S., Dörl, G., Milz, C., Kathofer, M., Stöhrmann, P., Gomola, D., Briem, E., Schlosser, G., Mayerweg, A., Semmelweis-Tomits, J., et al. (2024) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2024.2402261 · Cited by 2
“Thus, experiences of anxiety during ketamine application are categorised as adverse events and have been reported as a reason for discontinuation of treatment (Feifel et al. 2020).”
Almog, S., Weiner, M. D., Howarth, J., Becerra, J., Fux, J., & Berry, M. S. (2026) · Frontiers in Pain Research · doi:10.3389/fpain.2025.1675821 · Cited by 1
Sethuraman, R. M. (2022) · Saudi Journal of Medicine and Medical Sciences · doi:10.4103/sjmms.sjmms_234_21
“[2] A recently published study also concluded that the incidence of adverse effects was low and ketamine is reasonably safe even in the long‐term treatment of patients with depression based on the survey and the published studies.[3] It is important to note that the survey included specialists of diverse groups and th…”
BackgroundTherapeutic Use of Ketamine in Psychiatric Disorders
Jones, J., Morgan, C. J. A., & Malcolm, R. J. (2023) · Frontiers research topics · doi:10.3389/978-2-8325-1050-6
Ramm, R., Wiisanen, M., & DeMarco, M. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780197760864.003.0005
Ketamine toxicity: Translating preclinical findings to adverse effects in humans
Nezic, K., Ntafoulis, I., & Jacobs, G. E. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29930-8.00009-6
Clinician Education: Optimizing Music Choices for Ketamine-Assisted Psychotherapy
Chenette, C. I., & Chenette, C. I. (2024) · UA Campus Repository (The University of Arizona)
Untersuchung der Selbstmanagementfähigkeit depressiver Patienten
Schnierer, N. (2026) · heiDOK (Heidelberg University) · doi:10.11588/heidok.00037911
Horowitz, R. K., Rosa, W. E., Zarrabi, A. J., & Swogger, M. T. (2026) · Journal of Palliative Medicine · doi:10.1177/10966218251392787
Smith-Apeldoorn, S. Y., Veraart, J. K. E., Spijker, J., van der Meij, A., Kamphuis, J., & Schoevers, R. A. (2026) · Depression and Anxiety · doi:10.1155/da/8320239
“Overall, in line with previous research [10, 53], serious urinary tract problems related to ketamine or esketamine treatment seem uncommon.”
Metadata
- Authors
- Feifel, D., Dadiomov, D., & C. Lee, K.
- Affiliations
- University of California San Diego (US)
- University of Southern California (US)
- Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA 92037, USA
- Corresponding author
- Feifel, David
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2020-07-13
- Volume
- 13
- Issue
- 7
- Pages
- 151
- ISSN
- 1424-8247 (ISSN-L)
- PMC
- PMC7408561
- OpenAlex
- W3041232245
- Cited by
- 31
- References
- 38
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 6 · 2023: 4 · 2022: 6 · 2021: 5
- FWCI
- 2.25
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Pharmaceuticals (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
- Keywords
- ketamine, depression, repeated administration, drug safety, adverse events, treatment discontinuation, psychological distress, bladder dysfunction, cognitive decline, psychotic symptoms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
